8-K: Acrivon Reports Strong Clinical Data, Extends Runway

Acrivon Therapeutics announced positive clinical trial results for ACR-368 in endometrial cancer and ACR-2316 in lung cancer, alongside a cash runway into Q2 2027.

Summary

• Reported financial results for Q4 and full year ended December 31, 2025, showing a reduced net loss compared to the prior year.
• ACR-368, a CHK1/CHK2 inhibitor, demonstrated a confirmed overall response rate (cORR) of 52% in serous endometrial cancer (EC) subjects with up to two prior lines of therapy.
• Initiated Arm 3 of the registrational intent Phase 2b ACR-368 study (ACR-368 + ultra low-dose gemcitabine) in all-comer serous EC and plans to initiate Arm 4 (ACR-368 monotherapy) in 1H 2026.
• Completed exploratory Arm 2 of the ACR-368 study, supporting the efficacy and favorable tolerability of ultra low-dose gemcitabine sensitization in biomarker-negative subjects.
• ACR-2316, a WEE1/PKMYT1 inhibitor, showed favorable tolerability and promising clinical activity, including partial responses, in heavily pre-treated small cell lung cancer (SCLC) and squamous non-small cell lung cancer (sqNSCLC) in its Phase 1 trial.
• Nominated ACR-6840, an oral CDK11 inhibitor, as a new development candidate with an IND filing anticipated in Q4 2026.
• Cash, cash equivalents, and marketable securities totaled $118.6 million as of December 31, 2025, providing an expected operational runway into the second quarter of 2027.
• Launched a wholly-owned and operated CLIA-certified laboratory to support biomarker discoveries and companion diagnostics.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive update, driven by compelling clinical data for ACR-368 in a high-unmet-need cancer, promising early data for ACR-2316, and a solid financial runway, all underpinned by a robust precision medicine platform.

Positives

• ACR-368 achieved a significant confirmed overall response rate (cORR) of 52% in serous endometrial cancer, a high unmet need area.
• Expansion of the ACR-368 registrational intent study with new Arms 3 and 4 indicates confidence in the drug's potential.
• ACR-2316 demonstrated promising clinical activity and favorable tolerability in Phase 1, particularly in difficult-to-treat lung cancers.
• The company's cash position of $118.6 million provides an extended operational runway into Q2 2027.
• Reduced net loss for both the fourth quarter and full year 2025 compared to 2024.
• Decreased research and development expenses and general and administrative expenses year-over-year.
• Nomination of ACR-6840 expands the pipeline with a potential first-in-class CDK11 inhibitor.
• Establishment of a CLIA-certified laboratory strengthens precision medicine capabilities and biomarker development.

Risks

• Forward-looking statements are subject to inherent uncertainties, risks, and assumptions that are difficult to predict.
• Actual results could differ materially from those described in forward-looking statements due to various factors, including those detailed in the company's SEC filings under 'Risk Factors'.

Future Outlook

Acrivon Therapeutics anticipates several key milestones in 2026, including CTA approval in the EU for ACR-368 Arm 3, initial clinical data from Arm 3 and an update on Arm 1 by mid-2026, and the initiation of enrollment for ACR-368 Arm 4 in the first half of 2026. The company also expects to be ready for a Phase 3 confirmatory trial for ACR-368 in combination with PD-1 therapy by mid-2026 and to complete enrollment for Arm 3 by Q4 2026. For its broader pipeline, additional ACR-2316 Phase 1 clinical data and transition to dose expansion are expected in 2026, along with an IND filing for ACR-6840 in Q4 2026 and the initiation of new internal programs.

Management Comments

• Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon, stated, 'It's an exciting time for the company as we build on strong maturing data and clinical momentum.'
• Blume-Jensen highlighted that 'Our compelling data from ACR-368 in EC was well received at the ESGO Congress, reinforced by powerful commentary from world-renowned key opinion leaders.'
• Blume-Jensen emphasized, 'Serous EC represents a particularly significant unmet need with a mortality rate resulting in 40-50% of all EC deaths.'
• Blume-Jensen noted, 'Through our rapidly maturing data, we are strategically generating multiple opportunities towards potential registration for ACR-368, including our announcement today of a fourth arm to our study to investigate ACR-368 monotherapy in biomarker-unselected serous EC subjects.'
• Blume-Jensen also mentioned, 'Elsewhere in our pipeline, ACR-2316 has already shown promising clinical activity in lung cancer, underscoring the potential of its differentiated mechanism of action.'
• Blume-Jensen concluded, 'Finally, we continue to build our pipeline with our next development candidate, ACR-6840, and new programs, reflecting our sustained AP3-driven innovation and commitment to long-term value creation.'

Industry Context

StockSavvy.ai notes that Acrivon's focus on precision medicine, particularly in oncology with its AP3 platform, aligns with a major trend in the pharmaceutical industry towards targeted therapies. The strong cORR of 52% for ACR-368 in serous endometrial cancer addresses a high unmet need, as this subtype accounts for a significant portion of EC mortality and has limited effective treatment options. The promising early data for ACR-2316 in lung cancer, including SCLC and sqNSCLC, is notable given the historical challenges in treating these aggressive tumor types and the potential for WEE1/PKMYT1 inhibitors to offer new mechanisms of action. The company's proprietary AP3 platform and CLIA-certified lab position it to develop and validate companion diagnostics, a critical component for successful precision medicine drug commercialization.

Comparison to Industry Standards

• The 52% cORR for ACR-368 in serous EC with up to two prior lines of therapy significantly surpasses the typical ~15% ORR and ~3.4 months PFS observed with single-agent chemotherapy, which is the standard of care in the second line post-IO/platinum for this patient population.
• ACR-2316's observed clinical activity, including partial responses in SCLC and sqNSCLC, is noteworthy as these tumor types have not previously shown sensitivity to other WEE1 or PKMYT1 inhibitors currently in development, suggesting a potentially differentiated profile compared to competitors like AstraZeneca's adavosertib (WEE1 inhibitor) or other investigational agents.
• Preclinical data for ACR-2316 shows 5-20-fold more potency than clinical benchmarks and complete tumor regression, indicating a potentially superior therapeutic profile compared to existing or developing WEE1/PKMYT1 inhibitors.
• The favorable safety profile of ACR-368, with limited transient hematological adverse events and a notable absence of severe non-hematological toxicities, compares favorably to the broader toxicity profiles often seen with traditional chemotherapy or some targeted agents in oncology.

Stakeholder Impact

• **Shareholders**: Positive clinical data and extended cash runway could lead to increased investor confidence and potential share price appreciation. Future capital raises might dilute existing shareholders.
• **Patients**: The promising efficacy of ACR-368 in serous endometrial cancer and ACR-2316 in lung cancer offers hope for new treatment options in areas of high unmet medical need.
• **Employees**: Continued progress in clinical development and pipeline expansion suggests job stability and potential growth opportunities within the company.
• **Regulatory Authorities**: The company's engagement with the FDA (Fast Track, Breakthrough Device designations) and plans for EU approvals indicate adherence to regulatory pathways and potential for new drug approvals.
• **Healthcare Providers**: Successful development of these precision medicines could provide new tools for oncologists to treat challenging cancers, especially with the support of the CLIA-certified diagnostic lab.

Next Steps

• Achieve CTA approval in EU for the ongoing (US) registrational intent serous EC all-comer Arm 3 (ACR-368 + ULDG) by Q1 2026.
• Initial clinical data from Arm 3 and additional update on Arm 1 of the ACR-368 Phase 2b trial in mid-2026.
• Initiate enrollment for the registrational intent serous EC all-comer Arm 4 (ACR-368) in the US in first half of 2026.
• Achieve readiness for Phase 3 confirmatory trial for ACR-368 in combination with PD-1 therapy by mid-2026.
• Complete enrollment (up to N = 90 subjects) in the registrational intent serous EC all-comer Arm 3 (ACR-368 + ULDG) in Q4 2026.
• Additional ACR-2316 Phase 1 clinical data for weekly and bi-weekly dosing regimens and transition into dose expansion in AP3-identified tumor types in 2026.
• Submit IND filing to the FDA for ACR-6840 in Q4 2026.
• Initiate additional internal programs utilizing the AP3 platform in 2026.

Key Dates

Recommendation

The filing presents compelling positive clinical data for ACR-368 in a high-unmet-need indication (serous endometrial cancer), significantly outperforming current standard of care. The expansion of the registrational intent study and promising early data for ACR-2316 in difficult-to-treat lung cancers demonstrate a robust and advancing pipeline. Furthermore, the company has a solid cash position extending its runway into Q2 2027, reducing immediate financing concerns. The strategic focus on precision medicine with the AP3 platform and the establishment of a CLIA lab enhance long-term value creation. These factors collectively suggest a strong growth trajectory and significant upside potential for investors.

Keywords

Acrivon Therapeutics, ACRV, Endometrial Cancer, Serous EC, ACR-368, CHK1/CHK2 Inhibitor, ACR-2316, WEE1/PKMYT1 Inhibitor, Lung Cancer, Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer, ACR-6840, CDK11 Inhibitor, AP3 Platform, Generative Phosphoproteomics, OncoSignature, Clinical Trials, Biotechnology, Oncology, Precision Medicine, Financial Results, Cash Runway, SEC Filing, 8-K